Recent News

• 09.09.2025 - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
• 09.09.2025 - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
• 08.11.2025 - ArriVent BioPharma Reports Second Quarter 2025 Financial Results
• 08.11.2025 - ArriVent BioPharma Reports Second Quarter 2025 Financial Results
• 07.21.2025 - ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
• 07.21.2025 - ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026
• 07.07.2025 - Kaveri Pohlman
• 07.07.2025 - Kaveri Pohlman

Recent Filings

• 09.09.2025 - EX-99.1 EX-99.1
• 09.09.2025 - 8-K Current report
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 08.13.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.11.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.11.2025 - 8-K Current report
• 08.11.2025 - EX-99.1 EX-99.1
• 07.21.2025 - 8-K Current report